Pharmaceutical Risk-Sharing Agreements

被引:0
|
作者
Joseph P. Cook
John A. Vernon
Richard Manning
机构
[1] NERA Economic Consulting,Department of Finance
[2] The University of Connecticut,undefined
[3] Department of Economic Policy,undefined
[4] Pfizer Inc.,undefined
[5] The University of Connecticut,undefined
来源
PharmacoEconomics | 2008年 / 26卷
关键词
Bortezomib; Fair Trading; Pharmaceutical Expenditure; Branded Drug; Valuable Innovation;
D O I
暂无
中图分类号
学科分类号
摘要
Increased spending on pharmaceuticals continues to foster debate over healthcare policy. The increasing costs of bringing products to the market, as well as increased utilization of pharmaceuticals contribute to increased pharmaceutical expenditure; however, appropriate pharmaceutical use can, in certain cases, reduce overall healthcare costs. Nevertheless, the perception of high drug prices still puts pressure on pharmaceutical companies to build confidence in the proposition that their products are worth the additional expense. One potential approach to building this confidence, and maintaining investment incentives, is for the pharmaceutical company to share the risk of a situation in which there is uncertainty about whether the product is effective for the consumer and payer. Such risk-sharing arrangements for pharmaceuticals, like warranties, can be used to signal high quality when product quality is not fully observable. While there may be difficulties in devising such schemes for every product, such risk-sharing plans may become a staple feature of the market in the future.
引用
收藏
页码:551 / 556
页数:5
相关论文
共 50 条
  • [1] Pharmaceutical Risk-Sharing Agreements
    Afschin Gandjour
    PharmacoEconomics, 2009, 27 : 431 - 432
  • [2] Pharmaceutical risk-sharing agreements
    Cook, Joseph P.
    Vernon, John A.
    Manning, Richard
    PHARMACOECONOMICS, 2008, 26 (07) : 551 - 556
  • [3] Pharmaceutical Risk-Sharing Agreements
    Gandjour, Afschin
    PHARMACOECONOMICS, 2009, 27 (05) : 431 - 432
  • [4] THE SIMPLE ECONOMICS OF RISK-SHARING AGREEMENTS BETWEEN THE NHS AND THE PHARMACEUTICAL INDUSTRY
    Barros, Pedro Pita
    HEALTH ECONOMICS, 2011, 20 (04) : 461 - 470
  • [5] POTENTIAL RISK-SHARING AGREEMENTS FOR VACCINES
    Terlinden, A.
    Ethgen, O.
    Demarteau, N.
    Curran, D.
    VALUE IN HEALTH, 2014, 17 (07) : A669 - A670
  • [6] Where Are We on "Risk-Sharing" Agreements?
    Neumann, Peter J.
    VALUE IN HEALTH, 2013, 16 (05) : 701 - 702
  • [7] Risk-sharing agreements, present and future
    Goncalves, Francisco R.
    Santos, Susana
    Silva, Catarina
    Sousa, Gabriela
    ECANCERMEDICALSCIENCE, 2018, 12
  • [8] Health-based pharmaceutical pay-for-performance risk-sharing agreements
    Mahjoub, Reza
    Odegaard, Fredrik
    Zaric, Gregory S.
    JOURNAL OF THE OPERATIONAL RESEARCH SOCIETY, 2014, 65 (04) : 588 - 604
  • [9] The Impact of Two Pharmaceutical Risk-Sharing Agreements on Pricing, Promotion, and Net Health Benefits
    Zaric, Gregory S.
    Xie, Bin
    VALUE IN HEALTH, 2009, 12 (05) : 838 - 845
  • [10] Italian risk-sharing agreements on drugs: are they worthwhile?
    Livio Garattini
    Alessandro Curto
    Katelijne van de Vooren
    The European Journal of Health Economics, 2015, 16 : 1 - 3